Ruiz-Balaguer N, Nacher A, Casabo V G, Merino M
Department of Pharmaceutics, Faculty of Pharmacy, University of Valencia, Burjassot, Spain.
Antimicrob Agents Chemother. 1997 Feb;41(2):445-8. doi: 10.1128/AAC.41.2.445.
Cefuroxime is commercially available for parenteral administration as a sodium salt and for oral administration as cefuroxime axetil, the 1-(acetoxy)ethyl ester of the drug. Cefuroxime axetil is a prodrug of cefuroxime and has little, if any, antibacterial activity until hydrolyzed in vivo to cefuroxime. In this study, the absorption of cefuroxime axetil in the small intestines of anesthetized rats was investigated in situ, by perfusion at four concentrations (11.8, 5, 118 and 200 microM). Oral absorption of cefuroxime axetil can apparently be described as a specialized transport mechanism which obeys Michaelis-Menten kinetics. Parameters characterizing absorption of prodrug in free solution were obtained: maximum rate of absorption (Vmax) = 289.08 +/- 46.26 microM h-1, and Km = 162.77 +/- 31.17 microM. Cefuroxime axetil transport was significantly reduced in the presence of the enzymatic inhibitor sodium azide. On the other hand, the prodrug was metabolized in the gut wall through contact with membrane-bound enzymes in the brush border membrane before absorption occurred. This process reduces the prodrug fraction directly available for absorption. From a bioavailability point of view, therefore, the effects mentioned above can explain the variable and poor bioavailability following oral administration of cefuroxime axetil. Thus, future strategies in oral cefuroxime axetil absorption should focus on increasing the stability of the prodrug in the intestine by modifying the prodrug structure and/or targeting the compound to the absorption site.
头孢呋辛有可供肠胃外给药的钠盐制剂,也有可供口服的头孢呋辛酯,即该药物的1 -(乙酰氧基)乙酯。头孢呋辛酯是头孢呋辛的前体药物,在体内水解为头孢呋辛之前几乎没有抗菌活性(如果有也很微弱)。在本研究中,通过在四个浓度(11.8、5、118和200微摩尔)下灌注,对麻醉大鼠小肠中头孢呋辛酯的吸收进行了原位研究。头孢呋辛酯的口服吸收显然可描述为一种遵循米氏动力学的特殊转运机制。获得了表征前体药物在游离溶液中吸收的参数:最大吸收速率(Vmax)= 289.08±46.26微摩尔/小时,米氏常数(Km)= 162.77±31.17微摩尔。在存在酶抑制剂叠氮化钠的情况下,头孢呋辛酯的转运显著降低。另一方面,前体药物在吸收发生之前,通过与刷状缘膜中的膜结合酶接触而在肠壁中代谢。这个过程减少了可直接用于吸收的前体药物部分。因此,从生物利用度的角度来看,上述作用可以解释口服头孢呋辛酯后生物利用度的变化和不佳情况。因此,未来提高口服头孢呋辛酯吸收的策略应集中于通过修饰前体药物结构和/或将化合物靶向吸收部位来提高前体药物在肠道中的稳定性。